NASDAQ: INBSIntelligent Bio Solutions Inc Stock
$2.57-0.21 (-7.55%)
Updated Apr 24, 2024
INBS Price
$2.57
Fair Value Price
-$1.33
Market Cap
$5.52M
52 Week Low
$2.28
52 Week High
$49.20
P/E
-0.02x
P/B
1.68x
P/S
1.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.88M
Earnings
-$13.40M
Gross Margin
32.4%
Operating Margin
-457.69%
Profit Margin
-465.2%
Debt to Equity
1.73
Operating Cash Flow
-$7M
Beta
1.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INBS Overview
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INBS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INBS ($2.57) is overvalued by 293.02% relative to our estimate of its Fair Value price of -$1.33 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INBS ($2.57) is not significantly undervalued (293.02%) relative to our estimate of its Fair Value price of -$1.33 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INBS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INBS due diligence checks available for Premium users.
Be the first to know about important INBS news, forecast changes, insider trades & much more!
INBS News
Valuation
INBS fair value
Fair Value of INBS stock based on Discounted Cash Flow (DCF)
Price
$2.57
Fair Value
-$1.33
Undervalued by
293.02%
INBS ($2.57) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INBS ($2.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INBS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INBS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
30.46x
Market
41.27x
INBS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.68x
Industry
3.73x
INBS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INBS's financial health
Profit margin
Revenue
$917.3k
Net Income
-$2.0M
Profit Margin
-214.7%
INBS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
INBS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.8M
Liabilities
$5.7M
Debt to equity
1.73
INBS's short-term liabilities ($5.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INBS's short-term assets ($2.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INBS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
-$56.7k
Financing
$0.0
INBS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INBS vs Medical Device Stocks
Intelligent Bio Solutions Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.